Buy research grade Suptavumab biosimilar ，anti-REGN 2222, SAR-438584 antibody

Research Grade Suptavumab

Catalog #: DVV02807 Specific References (15) DATASHEET

SDS-PAGE for Research Grade Suptavumab ?>

SEC-HPLC for Research Grade Suptavumab ?>

Host species: Human

Isotype: IgG1, kappa

Applications: Research Grade Biosimilar

Expression system: Mammalian Cells

Overview

Catalog No.

DVV02807

Expression system

Mammalian Cells

Species reactivity

HRSV-A

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Applications

Research Grade Biosimilar

Target

F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

Concentration

1.64 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03420

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

H1H3592P3, REGN 2222, SAR-438584, SAR438584, REGN2222,CAS: 1629615-23-1

Clone ID

Suptavumab

Note

For research use only. Not suitable for clinical or therapeutic use.

Data Image

Bioactivity

Detects F/Fusion glycoprotein F0 in indirect ELISAs.
SDS-PAGE

SDS PAGE for Suptavumab
SEC-HPLC

The purity of this product is >95% as determined by SEC-HPLC.
Bioactivity

Detects HRSV-A2 Pre-F/Fusion glycoprotein F0 Protein in indirect ELISA.
Bioactivity

Detects HRSV Post-F/Fusion glycoprotein F0 Protein in indirect ELISA.
Bioactivity

Detects HRSV F/Fusion glycoprotein F0 Protein in indirect ELISA.
Bioactivity

The values represent the average 50% inhibitory concentration (IC50) [ng/mL] (fold change relative to the reference virus). The reference viruses were RSV-A and RSV-B strains without AA substitutions. Neutralization assays were conducted to evaluate the changes in susceptibility to palivizumab, suptavumab, and nirsevimab-mAbs that specifically bind to sites II, V, and Ø of the F protein, respectively-due to amino acid (AA) variations. The assays included one or two strains of RSV with specific AA substitutions, as well as reference strains of RSV-A and RSV-B without any AA substitutions. RSV replication was measured using enzyme-linked immunosorbent assay. Subsequently, the IC50 values were calculated using a nonlinear fit algorithm. Each measurement was conducted in duplicate.
Data sourced from citation (PMID: 39719011)
Bioactivity

Fig 1. Epitope-specific antibodies (ESA) levels at sites Ⅱ, Ⅲ, Ⅳ, Ⅴ, and Ø Serum ESA levels, measured using competitive enzyme-linked immunosorbent assay (ELISA) [μg/mL], a re shown for antigenic sites Ⅱ (palivizumab), Ⅲ (MPE8), Ⅳ (clesrovimab), Ⅴ (suptavumab), and Ø (nirsevimab). Serum samples were collected from 92 healthy adults aged 28-75 yea rs (median, 41.5 yea rs) between Februa ry and Ma rch 2020. Significant differences were observed across all combinations of ESA concentrations (p<0.001 for a ll compa risons).
Data sourced from citation (PMID: 40675573)

References

Respiratory Syncytial Virus Fusion Protein Epitope-specific Antibodies and Neutralizing Activities against Various Respiratory Syncytial Virus Strains. [DVV02807]

Antibodies to watch in 2017., PMID:27960628

Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem., PMID:29118126

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants., PMID:32897368

A systematic review on global RSV genetic data: Identification of knowledge gaps., PMID:34543489

Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis., PMID:36800182

Genetic characterization of respiratory syncytial virus surface glycoproteins F and G in Taiwan, 2017-2021., PMID:38937186

Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022., PMID:39048301

Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development., PMID:39209729

Amino acid substitutions in the fusion protein of respiratory syncytial virus in Fukushima, Japan during 2008-2023 and their effects., PMID:39719011

Human iPS cell-derived respiratory organoids as a model for respiratory syncytial virus infection., PMID:40262853

Amino acid substitutions in the fusion protein of respiratory syncytial virus in Fukushima, Japan during 2008-2023 and their effects. [DVV02807]

Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem, PMID: 29118126

Antibodies to watch in 2017, PMID: 27960628

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants, PMID: 32897368

Datasheet

Document Download

Research Grade Suptavumab.pdf

$ 530

Product specifications

1 mg 530 5 mg 1590 25 mg 4130

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here